In this issue:
Cancer risks in BRCA1 and BRCA2 mutation carriers
Pertuzumab + trastuzumab in HER2+ breast cancer
Hypofractionated postmastectomy radiation therapy
Cancer mortality rates have influenced global life expectancy
First-line alectinib vs crizotinib in ALK+ NSCLC
Racial disparities in risk of interval CRC
Nivolumab vs chemotherapy in NSCLC
Cetuximab or bevacizumab + chemotherapy in KRAS wt CRC
Prognostic value of LN yield in T1 CRC
Please login below to download this issue (PDF)